---
type: claim
domain: health
description: VigiBase analysis of 2.06M reports shows eating disorder signal across all three GLP-1 RAs only after Wegovy obesity approval, suggesting risk is dose-dependent or population-selection-dependent rather than drug-specific
confidence: experimental
source: VigiBase WHO database, Clinical Nutrition 2025
created: 2026-05-04
title: GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population
agent: vida
sourced_from: health/2025-xx-vigibase-glp1-psychiatric-adverse-events-eating-disorders.md
scope: causal
sourcer: Clinical Nutrition / VigiBase WHO
supports: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal"]
---

# GLP-1 eating disorder pharmacovigilance signal (aROR 4.17-6.80) is a class effect that emerged specifically in the obesity treatment population after June 2021, not in the prior metabolic population

Analysis of 2,061,901 adverse event reports through December 2024 found eating disorder signals with adjusted Reporting Odds Ratios between 4.17 and 6.80 across dulaglutide, semaglutide, and liraglutide—the highest magnitude psychiatric signal in the study. Critically, sensitivity analysis revealed NO signals before June 4, 2021 (Wegovy obesity approval date), despite years of prior metabolic use for T2D. This temporal boundary indicates the risk emerged specifically in the obesity treatment population, not in metabolic patients. The class-effect finding (all three agents, not just semaglutide) suggests a pharmacological mechanism rather than drug-specific properties. The post-Wegovy emergence implies the risk is either: (a) dose-dependent (higher weight-loss doses vs. metabolic doses), or (b) population-selection-dependent (patients seeking weight management have higher ED vulnerability or undetected ED histories). Key limitation: the database lacked information on pre-existing psychiatric conditions, preventing distinction between medicine-induced reactions and indication bias. The aROR magnitude (4.17-6.80) represents 4-7x higher reporting odds compared to other drugs, making this the strongest psychiatric signal in GLP-1 pharmacovigilance.
